Abstract: Etomoxir (2[6(4-chlorophenoxy) hexyl] oxirane-2-carboxylate) is a well-known irreversible inhibitor of carnitine palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme responsible for the transport of long-chain fatty acids into the mitochondria for β-oxidation. Originally explored for the treatment of metabolic and cardiovascular diseases, Etomoxir has garnered significant attention in the fields of oncology and immunometabolism. By blocking fatty acid oxidation (FAO), Etomoxir forces a metabolic shift toward glucose oxidation and induces profound effects on the tumor microenvironment, particularly influencing macrophage infiltration, the polarization of tumor-associated macrophages, and the function of myeloid-derived suppressor cells (MDSCs) and T-cells. Despite its potent pharmacological activity and ability to sensitize cancer cells to apoptosis, the clinical translation of Etomoxir has been severely hindered by its narrow therapeutic window, lack of isoform selectivity, off-target effects, and significant hepatotoxicity. This review synthesizes current literature on Etomoxir, focusing on its molecular mechanisms, structure-activity relationship, impact on immunometabolism, current limitations, and future therapeutic perspectives.
1. Introduction
Metabolic reprogramming is a hallmark of both cancer progression and immune cell activation. Fatty acid oxidation (FAO) is a critical bioenergetic pathway that occurs in the mitochondria, where long-chain fatty acids are truncated to generate NADH, FADH2, and acetyl-CoA for ATP production [1]. Carnitine palmitoyltransferase 1A (CPT1A) is the rate-limiting enzyme in this process, responsible for converting acyl-CoA into acyl-carnitine so it can cross the inner mitochondrial membrane [3]. Etomoxir, chemically known as 2[6(4-chlorophenoxy) hexyl] oxirane-2-carboxylate, is a potent, irreversible inhibitor of CPT1A [1]. While initially developed and tested in clinical trials for conditions such as heart failure and type 2 diabetes mellitus, Etomoxir has become a crucial pharmacological tool for investigating the role of lipid metabolism in cancer survival, immune evasion, and immunometabolism [2][4].
2. Pharmacological Activity
In the context of immunometabolism and macrophage polarization, Etomoxir exhibits significant pharmacological activity by modulating the metabolic dependencies of various immune cells within the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are heavily reliant on oxidative phosphorylation (OxPhos) and FAO to maintain their immunosuppressive, pro-tumorigenic phenotypes (such as the M2 macrophage polarization) [1]. The administration of Etomoxir has been shown to significantly delay tumor growth in vivo, an effect accompanied by a marked reduction in macrophage infiltration into the tumor [1]. Furthermore, the inhibition of CPT1A by Etomoxir enhances macrophage phagocytosis of tumor cells, particularly in models like glioblastoma multiforme (GBM), by counteracting immune evasion mechanisms linked to CD47 expression [3].
Beyond macrophages, Etomoxir impacts other critical immune populations. The inhibition of FAO modulates the immunosuppressive functions of MDSCs, thereby enhancing the efficacy of concurrent cancer therapies [1]. In T-cells, CPT1A-mediated long-chain FAO is essential for the development of CD8+ T-cell memory and protective immunity [2]. Additionally, Etomoxir has been shown to reverse programmed death-1 (PD-1)–driven increases in reactive oxygen species (ROS) in T-cells, highlighting the reliance of immune checkpoint signaling on fatty acid metabolism [1].
3. Molecular Mechanism of Action
The primary molecular mechanism of Etomoxir involves binding to the active site of CPT1A, acting as a strong and irreversible inhibitor [2][3]. By blocking CPT1A, Etomoxir prevents the influx of long-chain fatty acids into the mitochondria, which subsequently decreases mitochondrial β-oxidation. This blockade leads to an accumulation of fatty acids and lipids in the cytosol and forces the cell to shift its energy metabolism toward glucose oxidation and glycolysis [1][4].
In addition to its primary target, Etomoxir exerts several secondary and off-target molecular effects. It has been reported to hinder complex I of the mitochondrial electron transport chain (ETC) [1]. The disruption of FAO and the ETC by Etomoxir results in diminished intracellular ATP and NADPH levels, leading to severe oxidative stress and the activation of the proapoptotic LKB-1/AMPK pathway [1]. Furthermore, Etomoxir may directly activate peroxisome proliferator-activated receptor (PPAR) alpha, which paradoxically can upregulate a number of β-oxidation-related enzymes [4]. In cancer models, Etomoxir alters gene expression profiles associated with fatty acid metabolism, leading to cell cycle arrest and the inhibition of epithelial-mesenchymal transition (EMT) [1].
4. Structure-Activity Relationship (SAR)
Etomoxir belongs to a class of ethylene oxide compounds, specifically characterized as a glycidic acid derivative (2[6(4-chlorophenoxy) hexyl] oxirane-2-carboxylate) [1][3]. The oxirane (epoxide) ring is critical for its activity, allowing it to bind directly to the active site of the CPT1 enzyme, resulting in irreversible inhibition [2][3]. However, a significant limitation in the SAR of Etomoxir is its lack of isoform selectivity. While it is a potent inhibitor of CPT1A (the liver isoform), it also inhibits CPT1B (the muscle isoform), which contributes to its off-target effects and toxicity profile [2][3].
5. Current Limitations
Despite its efficacy in preclinical models, the clinical application of Etomoxir is severely restricted by its toxicity and off-target effects. The most prominent limitation is severe hepatotoxicity. Phase II clinical trials investigating Etomoxir for the treatment of moderate congestive heart failure (the ERGO study) were terminated prematurely due to significantly elevated liver transaminase levels in patients [3][4].
Additionally, Etomoxir possesses a very narrow therapeutic window. At commonly used experimental concentrations, it induces severe oxidative stress and disrupts mitochondrial energy metabolism [1][4]. Its lack of specificity for CPT1 isoforms means that it affects tissues reliant on CPT1B, such as the heart and skeletal muscle. In skeletal muscle, CPT1 inhibition by Etomoxir leads to excess triglyceride accumulation and lipotoxicity [5], and in the heart, it has been associated with the development of cardiac hypertrophy [4]. Furthermore, recent studies have identified that Etomoxir has off-target effects that inhibit cancer cell proliferation independent of its action on β-oxidation, complicating the interpretation of its metabolic efficacy [1][3].
6. Future Perspectives
The profound effects of Etomoxir on macrophage polarization, MDSC suppression, and tumor sensitization highlight CPT1A as a highly attractive therapeutic target, particularly at the intersection of oncology and immunometabolism. However, future drug development must focus on overcoming the structural limitations of Etomoxir. There is a critical need for the design of next-generation CPT1A inhibitors that possess high isoform selectivity (sparing CPT1B) and liver selectivity to avoid the hepatotoxicity and lipotoxicity associated with first-generation ethylene oxide compounds [3].
From a therapeutic standpoint, targeting lipid metabolism via CPT1A inhibition holds promise as a combination therapy. Preclinical evidence suggests that combining Etomoxir with radiotherapy, chemotherapy (such as cisplatin), or other metabolic inhibitors (like the glycolysis inhibitor 2-Deoxyglucose) can synergistically eliminate hypoxic tumor regions, overcome therapeutic resistance, and enhance anti-tumor immune responses [1][3]. If the toxicity profile can be managed through novel drug delivery systems or the development of safer analogs, targeting the FAO pathway could become a cornerstone strategy for reprogramming the immunosuppressive tumor microenvironment.
